Danny El-Nachef

Danny El-Nachef

Auto-generated profile, based on publicly available information

Danny El-Nachef

University of Washington

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Trends in Biotechnology
Verified
Journal Article
Closed access
CMChristian J. Mandrycky
Christian J. Mandrycky
NWNisa P. Williams
Nisa P. Williams
IBIvan Batalov
Ivan Batalov
DEDanny El-Nachef
Danny El-Nachef
BBBernadette Simone De Bakker
Bernadette Simone De Bakker
NSNathan Sniadecki
Nathan Sniadecki

20 April 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
DEDanny El-Nachef
Danny El-Nachef
DBDarrian Bugg
Darrian Bugg
KBKevin M. Beussman
Kevin M. Beussman
SSSonette Steczina
Sonette Steczina
AMAmy M. Martinson
Amy M. Martinson
JDJennifer Davis
Jennifer Davis

16 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KNKenta Nakamura
Kenta Nakamura
LNLauren E. Neidig
Lauren E. Neidig
XYXiulan Yang
Xiulan Yang
GWGerhard J. Weber
Gerhard J. Weber
DEDanny El-Nachef
Danny El-Nachef
CMCharles E. Murry
Charles E. Murry
Background Engraftment arrhythmias (EAs) are observed in large animal studies of intramyocardial transplantation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) for myocardial infarction. Although transient, the risk posed by EA presents a barrier to clinical translation. Objectives We hypothesized that clinically approved antiarrhythmic drugs can prevent EA-related mortality as well as suppress tachycardia and arrhythmia burden. Methods hPSC-CM were transplanted into the infarcted porcine heart by surgical or percutaneous delivery to induce EA. Following a screen of antiarrhythmic agents, a prospective study was conducted to determine the effectiveness of amiodarone plus ivabradine in preventing cardiac death and suppressing EA. Results EA was observed in all subjects, and amiodarone-ivabradine treatment was well-tolerated. None of the treated subjects experienced the primary endpoint of cardiac death, unstable EA or heart failure compared to 5/8 (62.5%) in the control cohort (hazard ratio 0.00; 95% confidence interval, 0–0.297; p = 0.002). Overall survival including two deaths in the treated cohort from immunosuppression-related infection showed borderline improvement with treatment (hazard ratio 0.21; 95% confidence interval, 0.03–1.01; p = 0.05). Without treatment, peak heart rate averaged 305 ± 29 beats per min (bpm), whereas in treated subjects peak daily heart rate was significantly restricted to 185±9 bpm (p = 0.006). Similarly, treatment reduced peak daily EA burden from 96.8 ± 2.9% to 76.5 ± 7.9% (p = 0.003). Antiarrhythmic treatment was safely discontinued after approximately one-month of treatment without recrudescence of arrhythmia. Conclusions The risk of engraftment arrhythmia following hPSC-CM transplantation can be reduced significantly by combined amiodarone and ivabradine drug therapy. Condensed Abstract Engraftment arrhythmia (EA) is a transient but serious complication of cardiac remuscularization therapy. Using a porcine model of cardiac remuscularization and EA, ivabradine and amiodarone were independently effective in suppressing tachycardia and arrhythmia, respectively. Baseline amiodarone combined with adjunctive ivabradine successfully prevented cardiac death, unstable EA and heart failure (hazard ratio 0.00; 95% confidence interval, 0–0.297; p = 0.002) and significantly suppressed peak daily heart rate and arrhythmia burden (p=0.006 and 0.003, respectively). Antiarrhythmic treatment was successfully discontinued after one-month without recrudescence of arrhythmia. We conclude that EA can be suppressed by combined amiodarone and ivabradine drug therapy.

26 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
DEDanny El-Nachef
Danny El-Nachef
AMAmy M. Martinson
Amy M. Martinson
XYXiulan Yang
Xiulan Yang
CMCharles E. Murry
Charles E. Murry
WMW. Robb MacLellan
W. Robb MacLellan
Histological analysis of fluorescently labeled tissues has been a critical tool to understand molecular organization in situ . However, assessing molecular structures within large cells and in the context of human organ anatomy has been challenging because it requires penetration of staining reagents and light deep into opaque tissues, while also conforming to the spatial constraints of high-resolution objective lenses. This methodology article describes optimized sample preparation for sub-micron resolution 3D imaging in human and rodent tissues, yielding imaging depth (>100 µm) and resolution (100 µm thick. This method can be readily adopted by any lab performing routine histology and takes 3 days from the start of tissue preparation to 3D images.

20 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
DEDanny El-Nachef
Danny El-Nachef
DBDarrian Bugg
Darrian Bugg
KBKevin M. Beussman
Kevin M. Beussman
AMAmy M. Martinson
Amy M. Martinson
CMCharles E. Murry
Charles E. Murry
JDJennifer Davis
Jennifer Davis
Preclinical studies have suggested that transplanted human pluripotent stem cell-derived cardiomyocyte (hPSC-CM) grafts expand due to proliferation. This knowledge came from cell cycle activity measurements that cannot discriminate between cytokinesis or DNA synthesis associated with hypertrophy. To refine our understanding of hPSC-CM cell therapy, we genetically engineered a cardiomyocyte-specific fluorescent barcoding system into an hPSC line. Since cellular progeny have the same color as parental hPSC-CMs, we could identify subsets of engrafted hPSC-CMs that clonally expanded, with the remainder being non-proliferative and hypertrophic.